No - on their website, they're referring to the Osiris product. You can tell by looking at the generic name (remstemcel-l). They obviously think that there's some value in that, though for the life of me, I can't think what.
Brand name? Again, I doubt it. Osiris were regarded as a failure in stem cells (and subsequently in oncology). Not sure what you'd get by preserving their name - or the name of a failed product - in perpetuity. Manufacturing facilities? Possibly - though they'd be pretty long in the tooth.
Agree - nothing wrong with getting indication in paediatrics first - though to go back to the origin of this thread, it doesn't help the resulting revenue line.
Speculation on Japanese revenue stream, page-15
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.040(4.08%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $1.743M | 1.708M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 34448 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 20058 | 20 |
View Market Depth
| Last trade - 10.35am 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |